Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

Back

ESC Premium Access

Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

Session: Antidiabetic drugs for treatment of cardiovascular disease

Topic: Heart Failure

Speaker: Mr F. Sinha (Regensburg, DE)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Mr Frederick Sinha

University Hospital Regensburg, Regensburg (Germany)

0 follower

7 more presentations in this session

Human epicardial adipose tissue-derived factors promote atrial endothelial dysfunction: role of pro-inflammatory cytokines and AT1R/NADPH oxidases/SGLT2 pro-oxidant pathway

Speaker: Doctor W. Fakih (Strasbourg, FR)

Takotsubo syndrome induced oxidative stress and endothelial dysfunction in left ventricle of rat model: association with NADPH oxidases/SGLT2 pro- oxidant pathway

Speaker: Miss T. Tatarcheh (Strasbourg, FR)

Investigating the effects of empagliflozin on myocardial metabolic and lipid profile in healthy and metabolic syndrome murine models following acute myocardial infarction

Speaker: Professor I. Andreadou (Athens, GR)

Semaglutide improves contractile function in isolated human atrium

Speaker: Doctor P. Hegner (Regensburg, DE)

Semaglutide modulates pro-inflammatory neutrophil phenotype induced by supraphysiological levels of the adipokine FABP4 in patients with cardiovascular disease.

Speaker: Doctor S. Eiras (Santiago de Compostela, ES)

Access the full session

Antidiabetic drugs for treatment of cardiovascular disease

Speakers: Mr F. Sinha, Doctor W. Fakih, Miss T. Tatarcheh, Professor I. Andreadou, Doctor P. Hegner...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources